维鲁科尼斯·加洛帕瓦 (Verruconis gallopava):一个伊萨夫科纳佐尼乌姆的敌人
Divisha Sharma1, Scott R Curry1, Courtney E Harris1
1Division of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA.
ASM case reports
|November 17, 2025
概括
Verruconis gallopava感染是罕见的,特别是在免疫功能低下的患者中. 在 isavuconazonium 失败后,Posaconazole (POS) 显示出临床改善,这表明POS是对V. gallopava.的潜在治疗方法.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 临床医学 临床医学
背景情况:
- Verruconis gallopava是一种环境真菌,很少引起人体感染,主要是免疫力低下的人.
- 感染可以表现为局部 (皮肤,肺) 或传播疾病,通常影响中枢神经系统.
- 对于V. gallopava感染,目前还没有标准化治疗指南,大多数三醇的体外抗真菌数据有限.
研究的目的:
- 在心脏移植后报告V. gallopava感染病例.
- 为了评估 isavuconazonium 和随后的 posaconazole 治疗的临床疗效.
- 为突出治疗挑战和潜在的治疗选择V. gallopava.
主要方法:
- 一个病例研究,一个免疫力低下的心脏移植接受者患有慢性肺炎.
- 经验性治疗以 isavuconazonium 进行,其次是脂质体安福特里辛 B 和口服波萨可纳.
- 来自和支气管支气管洗的真菌培养物识别了V. gallopava.
主要成果:
- 患者最初在经验性 isavuconazonium 治疗中恶化.
- 在呼吸道样本中,V. gallopava被确定为病原体.
- 过渡到波萨可纳导致症状的临床和放射性解决.
结论:
- 伊萨夫科纳佐尼姆证明了临床失败作为V. gallopava. 的经验性治疗.
- 在这种情况下,Posaconazole在治疗V. gallopava感染方面表现出有效性.
- 需要进一步的研究来确定V. gallopava感染的最佳治疗策略.
更多相关视频
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Antimicrobial Effectiveness
889
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
889
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420


